Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life : Insights From the STRONG-HF Trial
BACKGROUND: This analysis provides details on baseline and changes in quality of life (QoL) and its components as measured by EQ-5D-5L questionnaire, as well as association with objective outcomes, applying high-intensity heart failure (HF) care in patients with acute HF.
METHODS: In STRONG-HF trial (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) patients with acute HF were randomized just before discharge to either usual care or a high-intensity care strategy of guideline-directed medical therapy up-titration. Patients ranked their state of health on the EQ-5D visual analog scale score ranging from 0 (the worst imaginable health) to 100 (the best imaginable health) at baseline and at 90 days follow-up.
RESULTS: In 1072 patients with acute HF with available assessment of QoL (539/533 patients assigned high-intensity care/usual care) the mean baseline EQ-visual analog scale score was 59.2 (SD, 15.1) with no difference between the treatment groups. Patients with lower baseline EQ-visual analog scale (meaning worse QoL) were more likely to be women, self-reported Black and non-European (P<0.001). The strongest independent predictors of a greater improvement in QoL were younger age (P<0.001), no HF hospitalization in the previous year (P<0.001), lower NYHA class before hospital admission (P<0.001) and high-intensity care treatment (mean difference, 4.2 [95% CI, 2.5-5.8]; P<0.001). No statistically significant heterogeneity in the benefits of high-intensity care was seen across patient subgroups of different ages, with left ventricular ejection fraction above or below 40%, NT-proBNP (N-terminal pro-B-type natriuretic peptide) and systolic blood pressure above or below the median value. The treatment effect on the primary end point did not vary significantly across baseline EQ-visual analog scale (Pinteraction=0.87).
CONCLUSIONS: Early up-titration of guideline-directed medical therapy significantly improves all dimensions of QoL in patients with HF and improves prognosis regardless of baseline self-assessed health status. The likelihood of achieving optimal doses of HF medications does not depend on baseline QoL.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03412201.
| Errataetall: |
CommentIn: Circ Heart Fail. 2024 Apr;17(4):e011627. - PMID 38445961 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Circulation. Heart failure - 17(2024), 4 vom: 17. Apr., Seite e011221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Čelutkienė, Jelena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
114471-18-0 |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 18.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT03412201 CommentIn: Circ Heart Fail. 2024 Apr;17(4):e011627. - PMID 38445961 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCHEARTFAILURE.123.011221 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369357795 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369357795 | ||
| 003 | DE-627 | ||
| 005 | 20240418232706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCHEARTFAILURE.123.011221 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM369357795 | ||
| 035 | |a (NLM)38445950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Čelutkienė, Jelena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life |b Insights From the STRONG-HF Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03412201 | ||
| 500 | |a CommentIn: Circ Heart Fail. 2024 Apr;17(4):e011627. - PMID 38445961 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This analysis provides details on baseline and changes in quality of life (QoL) and its components as measured by EQ-5D-5L questionnaire, as well as association with objective outcomes, applying high-intensity heart failure (HF) care in patients with acute HF | ||
| 520 | |a METHODS: In STRONG-HF trial (Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) patients with acute HF were randomized just before discharge to either usual care or a high-intensity care strategy of guideline-directed medical therapy up-titration. Patients ranked their state of health on the EQ-5D visual analog scale score ranging from 0 (the worst imaginable health) to 100 (the best imaginable health) at baseline and at 90 days follow-up | ||
| 520 | |a RESULTS: In 1072 patients with acute HF with available assessment of QoL (539/533 patients assigned high-intensity care/usual care) the mean baseline EQ-visual analog scale score was 59.2 (SD, 15.1) with no difference between the treatment groups. Patients with lower baseline EQ-visual analog scale (meaning worse QoL) were more likely to be women, self-reported Black and non-European (P<0.001). The strongest independent predictors of a greater improvement in QoL were younger age (P<0.001), no HF hospitalization in the previous year (P<0.001), lower NYHA class before hospital admission (P<0.001) and high-intensity care treatment (mean difference, 4.2 [95% CI, 2.5-5.8]; P<0.001). No statistically significant heterogeneity in the benefits of high-intensity care was seen across patient subgroups of different ages, with left ventricular ejection fraction above or below 40%, NT-proBNP (N-terminal pro-B-type natriuretic peptide) and systolic blood pressure above or below the median value. The treatment effect on the primary end point did not vary significantly across baseline EQ-visual analog scale (Pinteraction=0.87) | ||
| 520 | |a CONCLUSIONS: Early up-titration of guideline-directed medical therapy significantly improves all dimensions of QoL in patients with HF and improves prognosis regardless of baseline self-assessed health status. The likelihood of achieving optimal doses of HF medications does not depend on baseline QoL | ||
| 520 | |a REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03412201 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a quality of life | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Natriuretic Peptide, Brain |2 NLM | |
| 650 | 7 | |a 114471-18-0 |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 700 | 1 | |a Čerlinskaitė-Bajorė, Kamilė |e verfasserin |4 aut | |
| 700 | 1 | |a Cotter, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Adamo, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Arrigo, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Barros, Marianela |e verfasserin |4 aut | |
| 700 | 1 | |a Biegus, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Chioncel, Ovidiu |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Solal, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Damasceno, Albertino |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Gayat, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Kimmoun, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Léopold, Valentine |e verfasserin |4 aut | |
| 700 | 1 | |a Metra, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Novosadova, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Pagnesi, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Peter S |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Saidu, Hadiza |e verfasserin |4 aut | |
| 700 | 1 | |a Sliwa, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Takagi, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Ter Maaten, Jozine M |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasoni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Carolyn S P |e verfasserin |4 aut | |
| 700 | 1 | |a Voors, Adriaan A |e verfasserin |4 aut | |
| 700 | 1 | |a Mebazaa, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Davison, Beth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Heart failure |d 2008 |g 17(2024), 4 vom: 17. Apr., Seite e011221 |w (DE-627)NLM187215812 |x 1941-3297 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g number:4 |g day:17 |g month:04 |g pages:e011221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCHEARTFAILURE.123.011221 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |e 4 |b 17 |c 04 |h e011221 | ||